AGENT FOR THE TREATMENT OF LEIOMYOMAS

The invention concerns anti-miRNA to be used for the treatment of uterine leiomyomas.
In particular, the proposed innovation aims at developing a biologic drug able to reduce the size of the leiomyoma, not only its symptoms, without interfering with ovulation cycles and patient fertility. This would therefore reduce the necessity of surgical intervention.

The invention concerns anti-miRNA for the treatment of leiomyoma,
in particular an inhibitor of one or more miRNA identified through a high throughput screen performed on human smooth muscle cells. Such inhibitor is preferably an LNA (locked nucleic acid). Uterine leiomyomas, commonly known as fibroids, affect 20%-50% of women in reproductive age, representing the most frequent type of benign gynaecological tumour. Current options include surgical removal and treatment with drugs that interfere with hormonal stimulation, which is the cause of their growth. As of today, there are no pharmacological therapies able to reduce the size of leiomyomas. Therefore, developing new conservative therapies able to either arrest or revert its growth, without interfering with ovulatory cycles and woman fertility, is of primary interest and has a wide market potential.

• Pharmaceutical sector.
• Treatment of uterine fibroids.

Possible Applications
• New biologic drug able to reduce the size of leiomyomas (not only the symptoms).
• Therapy not interfering with ovulatory cycles and fertility of the patient.
• Reduced need for surgery.
• Global market.

Patents publication numbers:
US20220333111 (2022-10-20)
EP4034657 (2022-08-03)
JP2022550073 (2022-11-30)
CN114544096 (2022-05-27)
WO2021/058524 (2021-04-01)
IT201900017234 (2021-03-25)

Manuscript under preparation